Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E17.08 EPS (ttm)5.25 Insider Own0.20% Shs Outstand773.50M Perf Week-3.18%
Market Cap69.31B Forward P/E8.84 EPS next Y10.14 Insider Trans-2.50% Shs Float749.91M Perf Month-5.06%
Income4.21B PEG0.88 EPS next Q1.96 Inst Own80.60% Short Float2.23% Perf Quarter-17.18%
Sales13.00B P/S5.33 EPS this Y109.10% Inst Trans-6.17% Short Ratio2.20 Perf Half Y-36.27%
Book/sh8.95 P/B10.01 EPS next Y19.93% ROA9.70% Target Price119.04 Perf Year-29.23%
Cash/sh15.57 P/C5.76 EPS next 5Y19.41% ROE35.80% 52W Range86.55 - 147.17 Perf YTD-14.13%
Dividend- P/FCF13.95 EPS past 5Y25.80% ROI29.40% 52W High-39.11% Beta1.54
Dividend %- Quick Ratio4.80 Sales past 5Y18.70% Gross Margin96.50% 52W Low3.54% ATR2.40
Employees7467 Current Ratio5.00 Sales Q/Q16.90% Oper. Margin35.80% RSI (14)39.44 Volatility2.14% 2.27%
OptionableYes Debt/Eq1.24 EPS Q/Q187.20% Profit Margin22.60% Rel Volume1.92 Prev Close89.91
ShortableYes LT Debt/Eq1.24 EarningsJan 25 BMO Payout0.00% Avg Volume7.62M Price89.61
Recom2.20 SMA20-2.70% SMA50-8.05% SMA200-23.81% Volume14,602,427 Change-0.33%
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-27-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-26-17Downgrade Wells Fargo Outperform → Market Perform
Oct-24-17Initiated Guggenheim Buy $160
Oct-23-17Resumed Piper Jaffray Neutral $133
Oct-20-17Reiterated UBS Buy $153 → $146
Oct-20-17Downgrade Robert W. Baird Outperform → Neutral $162 → $136
Oct-20-17Downgrade Citigroup Buy → Neutral
Oct-17-17Initiated Bernstein Outperform
Oct-05-17Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-17-18 02:00PM  Which Hot Biotech Name Will Be Acquired Next?
Mar-16-18 02:47PM  Why Cable News And Psoriasis Is A Match Made In Advertiser Heaven Forbes
Mar-15-18 11:47AM  Here's Why Shorting Geron Corporation Stock Is a Terrible Idea Motley Fool
Mar-14-18 04:52PM  Why Biotech Giant Celgene Should Consider Taking Itself Private Investor's Business Daily
02:54PM  Should Celgene Just Go Private?
12:45PM  Why Celgene's Beaten Down Stock Can Rise 28% Investopedia
06:04AM  3 Things You'll Want to Know From Celgene's 1st Public Event After the Ozanimod Debacle Motley Fool
Mar-13-18 02:35PM  Biogens Bargain Price May Spur a 14% Stock Gain Investopedia
09:00AM  3 Top Stocks Wall Street Is Overlooking Motley Fool
08:17AM  Near a 3-Year Low, Is Celgene Stock a Buy? Motley Fool
Mar-12-18 10:33AM  Good Reasons to Stick With Biotech ETFs ETF Trends
09:10AM  Todays Research Reports on Trending Tickers: Novavax and Celgene ACCESSWIRE
Mar-11-18 10:31PM  bluebird bio Inc (BLUE), Iqvia Holdings Inc (IQV): Four Biotech Stocks to Buy Now Insider Monkey
05:10PM  Top 3 Healthcare Stocks for 2018 Investopedia
11:33AM  The Revolutionary New HIV Drug You've Probably Never Heard Of Motley Fool
Mar-10-18 01:05PM  Corporate bio VCs are backing more rounds and making bigger bets TechCrunch
11:00AM  Top 5 Biotech Stocks for 2018 Investopedia
Mar-09-18 01:52PM  NYSE trader: Ride out this 9 year bull market for another 18 months Yahoo Finance Video
07:31AM  Jounce Therapeutics Is on Track to Report Key Data Soon Motley Fool
07:17AM  Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck Zacks
Mar-08-18 05:00PM  M&A, Innovation & New Drugs to Drive Pharma Stocks Zacks
08:19AM  Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta Zacks
08:05AM  Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck Zacks
Mar-07-18 04:33PM  Diplomat Pharmacy Filings Illustrate Competitive Pressure On AmerisourceBergen Forbes
04:00PM  Pharmaceutical Industry Outlook - March 2018 Zacks
03:49PM  Here's Why Editas Medicine Inc. Ticked Up Today Motley Fool
Mar-06-18 10:13AM  3 Growth Stocks at Deep-Value Prices Motley Fool
07:30AM  Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy Business Wire
Mar-05-18 11:59AM  Celgene Remains Promising Despite Significant Setback
10:52AM  Here's Why Celgene Corporation Fell in February Motley Fool
08:01AM  Stocks making the biggest moves premarket: XL, QCOM, AMZN, NWL & more CNBC
07:33AM  Benzinga's Bulls & Bears Of The Week: Fitbit, GE, Intel, Target, Walmart And More Benzinga
07:30AM  Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc. Business Wire
Mar-02-18 12:19AM  [$$] Can Celgene Save Itself? The Wall Street Journal
Mar-01-18 10:30PM  3 Biotech Stocks I Love for March (Celgene Is One of Them)
07:00PM  Cramer's sell-off strategy: This is a great opportunity t... CNBC Videos
12:54PM  Sorry Celgene. Bigger Isn't Better in Biotech.
12:30PM  3 Biotech Stocks That May Be On The Verge Of Sharp Declines Investopedia
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celgene Corporation (CELG) PR Newswire
09:35AM  Celgene's $6 Billion Blunder: Time to Throw in the Towel on the Biotech Stock? Motley Fool
09:00AM  3 Promising Biotech Stocks to Buy on Dips
08:21AM  Celgene shares drop 9% after blunder with high-profile drug MarketWatch
08:20AM  Todays Research Reports on Stocks to Watch: Sorrento Therapeutics and Celgene Corporation ACCESSWIRE
05:30AM  [$$] Can Celgene Save Itself? The Wall Street Journal
Feb-28-18 05:25PM  US STOCKS-Wall St slides late; S&P 500 caps worst month since Jan 2016 Reuters -9.04%
05:03PM  What Happened in the Stock Market Today Motley Fool
04:45PM  GLOBAL MARKETS-Dollar rises on Powell's economic outlook, stocks slip Reuters
04:24PM  How Celgene 'Gambled' On Ozanimod And Why It Didn't Pay Off Investor's Business Daily
03:31PM  US STOCKS-Wall St falls with energy; S&P set for biggest monthly fall since 2016 Reuters
03:15PM  GLOBAL MARKETS-Dollar gains on Powell's economic outlook, stocks slip Reuters
02:30PM  Celgene's Run of Bad Luck Continues Motley Fool
02:15PM  Earnings movers in the trader blitz, plus Weiss' new buys CNBC Videos
02:01PM  Apple, Expedia, Lowe's, Celgene & Cisco CNBC Videos
01:36PM  Was Celgene's Acquisition of Receptos a Huge Mistake?
01:35PM  Credit Suisse: Celgene Needs To Win Back Investor Trust Benzinga
01:26PM  US STOCKS-Strong retail earnings help Wall St bounce off lows Reuters
01:26PM  Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo Zacks
01:24PM  [$$] Selling Celgene, Buying Time Warner, AT&T
12:15PM  Biotech ETFs fall, led by Celgene MarketWatch
12:09PM  One Big Stumble for Celgene, One Small Drop for Biotech
11:52AM  Celgene's 3 Key Financial Ratios (CELG) Investopedia
11:46AM  US STOCKS-Wall St pares gains as energy, health stocks drag Reuters
10:05AM  US STOCKS-Wall St climbs after GDP growth revised lower Reuters
10:04AM  Celgene Shares Tank on Multiple Sclerosis Drug Application Setback
09:56AM  Celgene's Execution Problems Are Beyond the Pale Bloomberg
09:16AM  US STOCKS-Futures climb after downward revision of GDP data Reuters
09:15AM  5 of the Most Disruptive Stocks in Healthcare Motley Fool
08:28AM  US STOCKS-Wall St on course for February loss, first in 11 months Reuters
07:20AM  Celgene Sinks After FDA Calls Drug Application 'Insufficient' Investopedia
Feb-27-18 05:51PM  After-hours buzz: ETSY, ELF, ESRX, CELG & more CNBC
05:37PM  Celgene Tanks After FDA Refuses To Review Multiple Sclerosis Drug Investor's Business Daily
04:58PM  Celgene shares drop after FDA refuses multiple sclerosis drug application MarketWatch
04:30PM  Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis Business Wire
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conferences Business Wire
Feb-26-18 05:46AM  Celgene (CELG) Down 8.4% Since Earnings Report: Can It Rebound? Zacks
Feb-24-18 01:00PM  What does it take to be a startup that raises huge sums quickly? TechCrunch
10:32AM  In Your 60s? 3 Stocks You Should Consider Buying Motley Fool
Feb-23-18 07:09PM  3 Big Drugmakers Boosting Huge R&D Budgets Motley Fool
01:32PM  Stocks are coiling for the next big move Yahoo Finance Video
09:12AM  These 2 Biotech Stocks Are Soaring. Can They Keep It Up? Motley Fool
07:40AM  Blog Exposure - Celgene Gets Antitrust Clearance for Junos Acquisition ACCESSWIRE
06:04AM  Better Buy: Biogen Inc. vs. Celgene Corporation Motley Fool
06:00AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Feb-22-18 06:07PM  bluebird bio Updates Plans for the Year Ahead Motley Fool
08:33AM  Merck to Buy Australian Firm to Boost Immunotherapy Pipeline Zacks
Feb-21-18 01:29PM  Washington, DC is not helping NJ: Bob Hugin Fox Business Videos
07:30AM  Celgene Receives Antitrust Clearance for Juno Acquisition Business Wire
06:31AM  The 1 Stock You've Been Overlooking for Your Roth IRA Motley Fool
Feb-20-18 12:27PM  Incyte (INCY) Q4 2017 Earnings Conference Call Transcript Motley Fool
07:00AM  Pharmaceutical Titans Senate Bid Will Test Voters Views on Drug Prices Bloomberg
Feb-19-18 08:43AM  Celgene Reports Positive Data on Dermatology Drug Otezla Zacks
07:32AM  Buy Biogen Stock on the Dip? Motley Fool
07:00AM  Is AbbVie or Gilead Sciences Stock a Better Buy? Motley Fool
Feb-17-18 04:00PM  OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçets Disease with Oral Ulcers Business Wire
10:31AM  How Celgene Hopes to Cash In on CAR-T Motley Fool
Feb-16-18 01:28PM  What You Must Know About Celgene Corporations (NASDAQ:CELG) ROE Simply Wall St.
01:05PM  Why 2018 Could Be An Explosive Year For Biotech Mergers Investor's Business Daily
09:40AM  Billionaire Ray Dalio's Bridgewater Bets Big on ETFs: 13F Filing Investopedia
07:31AM  5 Things You Need to Know About Celgene's Future Motley Fool
Feb-15-18 02:32PM  [$$] Buying AMD, Intel, Union Pacific, Selling Wells Fargo
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; and Jounce Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 17Option Exercise0.007,2830186,187Feb 20 05:00 PM
Smith Scott AndrewSee RemarksFeb 17Option Exercise0.007,283051,748Feb 20 05:03 PM
KELLOGG PETER NSee RemarksFeb 17Option Exercise0.007,283049,660Feb 20 05:03 PM
KAPLAN GILLADirectorFeb 15Option Exercise27.189,250251,41594,801Feb 20 05:02 PM
KAPLAN GILLADirectorFeb 15Sale95.999,250887,89885,551Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM